FOR IMMEDIATE RELEASE:

Open Source Health announces Edison de Mello, M.D., Ph.D., leader in Integrative Medicine to the Medical Advisory Board

Toronto, Ontario, Canada – July 21, 2016: Open Source Health Inc. (CSE:OSH), (Frankfurt:0OS), a cloud based precision medicine platform for women that puts control into the hands of women to educate, advocate and collaborate on their own healthcare is pleased to announce that Dr. Edison de Mello, of Santa Monica, California has joined the Medical Advisory Board of OSH.

“Dr. de Mello is a tremendous addition to the Medical Advisory Board of OSH” says Sonya Satveit, CEO of Open Source Health Inc. “With dual expertise as a board-certified Integrative Health Care Physician and a Licensed Psychotherapist, he brings vast experience and the immense resources of the Akasha Center for Integrative Medicine to help advance the myAva platform.”

“Sonya’s passion, dedication and clear vision for this project is remarkable, inspiring and filled with hope for the future of healthcare. I am honored to be part of OSH’s Medical Advisory Team, ” states Dr. Edison de Mello, “When I mentioned myAva’s platform to a group of doctors in Brazil, their faces lit up because they see so many women with PCOS and have so very little to offer them. So Brazil, here we come … very soon.”

As an expert member of our Advisory Board, Dr. de Mello will help guide the development of our myAva platform for the delivery of precision medicine. Dr. de Mello currently treats women with PCOS, the leading cause of infertility which affects up to 7 million women in America and is one of the most underserved of all women’s health issues. Approaching this complex syndrome at the molecular level will help achieve a new understanding of PCOS and has the potential to provide precision integrative treatment programs based on each woman’s unique circumstances.

OSH has granted Dr. de Mello 100,000 stock options for his participation on the Advisory Board.

About Dr. de Mello:

The Founder and Chief Medical Officer of the Akasha Center for Integrative Medicine, Edison de Mello, M.D., Ph.D., is a board certified Integrative Physician by the American Board of Integrative Medicine and a licensed psychotherapist by the California Board of Behavioral Sciences. He practiced psychotherapy for 13 years before entering medical training and now practices and teaches evidenced-based integrative medicine.

Dr. de Mello’s PhD dissertation, entitled “Gut Feelings – A Psychosocial Approach to Gastrointestinal Illness,” inspired his conception of a center where psychology would be combined and fully integrated with Western and Eastern medicines. The de Mello Institute was formed in 1996 with the goal of employing safe and complementary approaches to healthcare while also addressing a person’s...
emotional and spiritual health. Fully committed to these goals, Dr. de Mello entered residency in 1999 at the prestigious Albert Einstein College of Medicine at Beth Israel Medical Center Urban Family Residency program in New York City, including training at the Manhattan-based Center for Health and Healing. His training utilized a bio-psychosocial model and offered innovative experiences in the integration of complementary medicine into the practice of Family Medicine.

Upon completing his medical training, Dr. de Mello expanded the de Mello Institute and founded the Akasha Center for Integrative Medicine. Envisioned as a “healing sanctuary,” where all parts that compose a person, namely mind, body and spirit, are equally addressed when treating and preventing disease, The Akasha Center exemplifies Dr. de Mello’s vision and strong commitment to the practice of integrative medicine. His goal is to help every patient get the best out of the integration of science-proven approaches to medicine, drawing from both the technological advances of the West and the ancient wisdom of the East.

For more information on Dr. de Mello or Akasha Center for Integrative Medicine please visit the web site:  http://akashacenter.com/

About Open Source Health Inc.:

OSH has developed a cloud-based precision medicine platform called myAva, which is licensed to clinics and providers to enable the delivery of precision medicine, specifically for women’s health. By collecting and analyzing molecular-level data we will create a digital version of each patient, uncovering disease markers at an early stage allowing women and their providers to take a proactive approach to achieve optimal health. myAva sets the new standard of care for women’s health. The initial launch of myAva is focused at PCOS (Polycystic Ovary Syndrome), which affects 7 million women in the United States and 116 million women worldwide.

For more information, visit www.opensourcehealth.com

Contact:

For further information, please contact Investor Relations at Open Source Health Inc.
Toll Free: 1.866.403.1933 in North America
International Calling: +01.647.872.9986
http://www.opensourcehealth.com/contact-new/

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Open Source Health Inc. (“OSH”), including, but not limited to, the impact of general economic conditions, industry conditions and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

The forward-looking statements contained in this press release are made as of the date of this press release, and OSH does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.